1-4 of 4
Fenghuang Zhan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma

Mason McCrury, Kennith Swafford, Sydnye L. Shuttleworth, Syed Hassan Mehdi, Baku Acharya, Debasmita Saha, Kevin Naceanceno, Stephanie D. Byrum, Aaron J. Storey, Ying-Zhi Xu, Claire Doshier, Vijay Patel, Ginell R. Post, Annick De Loose, Analiz Rodriguez, Leonard D. Shultz, Fenghuang Zhan, Donghoon Yoon, Brendan Frett, Samantha Kendrick
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (3): 316–329.
https://doi.org/10.1158/1535-7163.MCT-23-0299
Published: 04 March 2024
View articletitled, Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
Open the PDF for Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma in another window
Includes: Supplementary data
Journal Articles

Abstract B38: Targeting FOXM1 in multiple myeloma

Van S. Tompkins, Zhimin Gu, Hongwei Xu, Guido Tricot, Fenghuang Zhan, Siegfried Janz
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (5_Supplement): B38.
https://doi.org/10.1158/1535-7163.PMS-B38
Published: 01 May 2014
View articletitled, Abstract B38: Targeting FOXM1 in multiple myeloma
Journal Articles

Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model

Holly A.F. Stessman, Linda B. Baughn, Aaron Sarver, Tian Xia, Raamesh Deshpande, Aatif Mansoor, Susan A. Walsh, John J. Sunderland, Nathan G. Dolloff, Michael A. Linden, Fenghuang Zhan, Siegfried Janz, Chad L. Myers, Brian G. Van Ness
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (6): 1140–1150.
https://doi.org/10.1158/1535-7163.MCT-12-1151
Published: 09 June 2013
View articletitled, Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model
Open the PDF for Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model in another window
Includes: Supplementary data
Journal Articles

Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma

Frits van Rhee, Susann M. Szmania, Myles Dillon, Anne M. van Abbema, Xin Li, Mary K. Stone, Tarun K. Garg, JuMei Shi, Amberly M. Moreno-Bost, Rui Yun, Balaji Balasa, Bishwa Ganguly, Debra Chao, Audie G. Rice, Fenghuang Zhan, John D. Shaughnessy, Jr., Bart Barlogie, Shmuel Yaccoby, Daniel E.H. Afar
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (9): 2616–2624.
https://doi.org/10.1158/1535-7163.MCT-09-0483
Published: 17 September 2009
View articletitled, Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
Open the PDF for Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma in another window
Includes: Supplementary data